A straightforward microwave method for rapid synthesis of N-1, C-6 functionalized 3,5-dichloro-2(1H)-pyrazinones[†]


Johan Gising, Pernilla Örtqvist, Anja Sandström and Mats Larhed*

Received 18th March 2009, Accepted 15th April 2009 First published as an Advance Article on the web 27th May 2009 DOI: 10.1039/b905501k

A rapid and versatile one-pot, 2×10 min microwave protocol for the preparation of N-1 and C-6 decorated 3,5-dichloro-2(1*H*)-pyrazinones was developed. Comparable reaction sequences using classical conditions require about 1–2 days of heating. The α -aminonitrile was first generated in a Strecker reaction and thereafter cyclized under microwave heating. The microwave approach developed offers the possibility of efficiently generating and utilizing functionalized 3-amino-5-chloro-2(1*H*)-pyrazinone-N-1-carboxylic acids as β -strand inducing core structures in a medicinal chemistry context. To illustrate the usefulness of the method, the synthesis of two novel 2(1*H*)-pyrazinone-containing Hepatitis C virus NS3 protease inhibitors is reported.

Introduction

Derivatives of 2(1H)-pyrazinones have wide-spread biological activities1-3, are classified as important drug scaffolds, and are known β-strand^{4,5} conformation inducers.^{6,7} Thus, these heterocyclic systems are of general interest to medicinal chemists. However, there are only a few synthetic approaches to N-1, C-3, C-6-trisubstituted 2(1H)-pyrazinones in the literature.^{6,7} A powerful synthetic procedure reported by Hoornaert et al.8 employs a primary amine (1), an aldehyde (2) and a cyanide source to give an intermediate α -aminonitrile (3) in a Strecker type reaction (Scheme 1, Step 1). The reaction mixture is thereafter treated with HCl and oxalyl chloride, and the resulting chlorinated oxamoyl derivative is slowly cyclized at room temperature for two days,⁹ or under traditional heating at 80–100 °C for 4–6 h,⁸ to afford the desired N-1, C-6-disubstituted 3,5-dichloro-2(1H)pyrazinone (4) in moderate to good yields (Scheme 1, Step 2). The use of formaldehyde as the C-6 source also provides the opportunity to keep this ring position unfunctionalized. Although Hoornaert's reaction sequence suffers from the requirement of



Scheme 1 Two-step synthesis of N-1, C-6-disubstituted 3,5-dichloro-2(1H)-pyrazinones (4).

prolonged reaction times, a hazardous cyanide source and a purification procedure for the intermediates, it is the only versatile protocol available for the preparation of N-1, C-6-disubstituted 3,5-dichloro-pyrazinones **4**. Furthermore, different functionalities might be introduced at the C-3 position of **4** using the reactive imidoyl chloride moiety.^{6,7,10}

The development of new high-speed chemistry procedures continues to be a prioritized area for modern drug discovery.^{11,12} Heterocyclic systems of interest in drug discovery projects must be rapidly constructed, purified, characterized, and evaluated. In this area, controlled microwave radiation has proven to be a valuable tool for enhancing reaction rates and synthetic productivity, especially for the straightforward generation of functionalized azaheterocycles.¹³⁻¹⁵


In this short article, we present the successful application of high-density microwave heating for: (1) the fast one-pot, two-step synthesis of N-1, C-6-disubstituted 3,5-dichloro-2(1*H*)-pyrazinones (4); (2) the rapid 10 min ring-closure of α -amino-nitriles **3** to provide synthetically demanding products of class **4**; and (3) the preparation and biological testing of two new peptidomimetic Hepatitis C virus NS3 protease inhibitors comprising a N-1, C-3, C-6 functionalized 2(1*H*)-pyrazinone structure.

Results and discussion

The first aim of this investigation was to develop a fast and convenient one-pot, two-step microwave procedure for synthesis of 3,5-dichloro-2(1H)-pyrazinones 4. Initially, 10 min microwave-assisted Strecker experiments were carried out in sealed vessels using 1.0 mmol primary amine, 1.2 equiv. aldehyde, and 1.1 equiv. trimethylsilyl cyanide¹⁶ in 1,2-dimethoxyethane (DME) to assess the appropriate reaction temperature for each individual step 1 reaction (Scheme 2). The choice of reaction temperature was not self-evident but varied considerably between different reactant combinations. The temperature optimization was performed using at least three different reaction temperatures with 20 °C difference. To qualitatively compare the outcome of the reactions, all reaction mixtures were analyzed by RP-HPLC/UV at 254 nm, and the peak

Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala Biomedical Centre, Uppsala University, Box 574, SE-751 23, Uppsala, Sweden. E-mail: mats@orgfarm.uu.se; Fax: +46 18 4714474; Tel: +46 18 4714667

[†] Electronic supplementary information (ESI) available: Experimental details, UV/ELSD, ESI-MS, ¹H and ¹³C NMR spectra of products. See DOI: 10.1039/b905501k




Scheme 2 One-pot, two-step microwave synthesis of N-1, C-6-disubstituted 3,5-dichloro-2(1H)-pyrazinones (4).

area ratio between 3 and 1 was used as the productivity response. If the starting amine 1 did not have a useful UV absorption, ELSD detection or MS detection was applied. The results obtained during these studies provided the selected temperatures for the Step 1 Strecker transformation. In successful reactions with full consumption of amine 1, intermediate 3 was not purified but instead the solvent was evaporated and the crude material was dissolved in diethyl ether and directly treated with HCl gas. Thereafter, the solvent was again evaporated, the solid HCl salt of 3 was suspended in DME and 2.5 equiv. of oxalyl chloride was added to the reaction mixture. The reaction vial was sealed and the content was heated by controlled microwave irradiation at 170 °C for 10 min (Scheme 2, Step 2).

By using a purpose built microwave synthesizer, together with the appropriate 5 mL reaction vials, the protocol is safe and convenient to carry out. In all cases, the maximum reaction pressure (<20 bar) during step 2 did not disturb the microwave processing. The preparative results of the two-step methodology are depicted in Table 1. In those cases where it was difficult to identify a suitable temperature for producing aminonitrile 3, several temperatures were employed and the preparative results were evaluated by completing the ring closure and determining the isolated yield of pure pyrazinone product 4 (Table 1, entries 2, 5, 6, 9, 10, 11 and 13). Entry 5 provides an illustrative example in which intermediate **3e** was produced *in situ* by heating for 10 min at $60 \,^{\circ}$ C, 80 °C, or 100 °C, and then cyclized to afford the isolated product 4e in 79%, 74%, and 74% yield, respectively. Generally, complete conversions of 1 and 3 were efficiently achieved with reactive primary amines 1a-d, 1f-h, and acetaldehyde (2a), providing products 4a,e-g,j,k,m in 41-79% two-step isolated yields. Benzaldehyde (2b) and the brominated derivatives 2c and 2d furnished somewhat lower yields of 4 (43-58%) compared with analogous reactions of 2a (compare e.g. entry 1 with entries 2-4). A similar trend was also noted when comparing 2a with the formal dehyde source 2e^{17,18} as the electrophile (Table 1, entry 12 and 14). The use of the weak nucleophile aniline (1e) afforded only low yields of 4i (27-29%), while the ester protected amino acids 1f-h served as more efficient nucleophiles (38-63%, entries 9-14). Importantly, the valine derivative 1f and the protected phenylalanine 1h reacted without any detected racemization despite the high temperature and acidic reaction conditions (entries 10,13,14).¹⁹ Please note that the hydrochloride salt of 1h was used in entry 14. The one pot twostep protocol could also be performed on a 2 mmol scale (entry 10) and on a 5 mmol scale (entry 13). In the 5 mmol reaction, a 20 mL sealed vessel was used instead of the previously employed 5 mL vial and the temperature and time were modified in step 2 to 145 °C for 25 min in order to reduce the maximum reaction pressure

(<20 bar). The isolated yields were more or less identical regardless of whether they were determined from 1.0, 2.0 or 5.0 mmol scale reactions (45–51%, 53% and 55%). When comparing the results from Table 1 with the available literature data,^{8,9,20–22} the one-pot, two-step microwave protocol developed provides the same or a slightly improved outcome with respect to the isolated yield of pyrazinone **4** using classical heating.

In the case of preparative handling and reaction speed, the microwave protocol is superior with reaction times being reduced from days or hours down to 2×10 min. In the case of weakly nucleophilic aniline (1e, Table 1, entry 9), amino acid derivatives, and formaldehyde (2e), it was advantageous to either purify aminonitrile 3, or use commercially available 3, before HCl enrichment, addition of oxalyl chloride and subsequent ring-closing (Scheme 3).



Scheme 3 One-step microwave synthesis of N-1, C-6-disubstituted 3,5-dichloro-2(1H)-pyrazinones (4) starting from pure α -aminonitriles (3).

Thus, when LC-MS analysis indicated the formation of byproducts, degradation of starting materials, or incomplete conversion from 1 to 3 in the Strecker reaction, the crude reaction mixtures were passed through a short column of silica gel before the final cyclization. The pure α -aminonitriles 3 were enriched with HCl gas in diethyl ether and thereafter smoothly cyclized with oxalyl chloride in DME, employing microwave heating at 170 °C for 10 min, proving good one-step yields of pyrazinone products **4i**, **4o-s** (Table 2, 56–86%). As expected, the one-step protocol gave better yields than the one-pot, two step method, see entry 9, Table 1 (27–29% of **4i**) and entry 1, Table 2 (70% of **4i**). When compared with reported cyclizations under classical conditions, the microwave approach gave improved or at least similar isolated yields (Table 2).^{8,23–25}

Proteases are involved in many pathological conditions, and consequently, these enzymes are also important drug targets. The natural substrates of proteases are generally assumed to adopt an extended conformation prior to binding the enzymes (Chart 1, I), and 2(1H)-pyrazinones substituted by an RNH group in the C-3 position and with an amino acid C-terminal incorporated in the N-1, are known β -strand conformation inducers (Chart 1, II).^{4,5} Since pre-organizing and rigidifying inhibitors in the proper conformation for binding to the target is a way to increase their activity, this is a very interesting aspect of the pyrazinone core from a medicinal chemistry point of view. In the case of Hepatitis C virus (HCV) NS3 protease inhibitors, there are earlier examples of rigidification by macrocyclization²⁶ as well as by incorporation of heterocycles^{4,27,28} in the inhibitor backbone. We have previously reported on the discovery of *p*-substituted phenylglycine as a promising P2 residue (standard nomenclature according to Schechter and Berger²⁹) in tripeptide (HCV) NS3 protease inhibitors.³⁰ Aiming at inhibitors with increased rigidity, decreased peptide character and decreased molecular weight, we became interested in introducing the pyrazinone-phenylglycine

Entry	Amine	Aldehyde	Temp Step 1 (°C)	Product	Isolated yield ^b
1	NH ₂ 1a	0 2a	60		72%
2	NH ₂ 1a	O 2b	60 80		58% 56%
3	NH ₂ 1a	C C Br 2c	60	Br N O CI N CI 4c	57%
4	NH ₂ 1a	Br 2d	80	Br CI N CI 4d	43%
5	NH ₂	0 9 2a	60 80 100		79% 74% 74%
6	NH ₂	0 2a	60 80		67% 62%
7	NH ₂	0 2a	80		55%
8	NH ₂	O ₽ 2b	80		38%
9	1e NH2	0 2a	80 100		29% 27%

Table 1	Microwave-accelerated one-pot, ty	vo-step synthesis of N-1. C-6-disul	bstituted 3,5-dichloro-2(1H)-pyrazino	nes (4a–n) according to Scheme 2 ^{<i>a</i>}

Entry	Amine	Aldehyde	Temp Step 1 (°C)	Product	Isolated yield ^b
10	O If O If NH ₂	O 2a	80 100 80		45% 51% 53% ^c
11	O NH ₂ 1g	0 2a	80 100		44% 41%
12	O NH2	O ∥ 2e NaHSO₃	170		38%
13	O O NH ₂	O 2a	80 100 80		56% 63% 55% ^d
14	HCI NH ₂	O ∥ 2e NaHSO₃	170		54%

^{*a*} Step 1 was performed with 1.0 mmol of 1, 1.2 equiv. of 2, and 1.1 equiv. of trimethylsilyl cyanide in 3.0 mL of DME with microwave heating in a sealed 5 mL vial for 10 min at the stated temperature. Step 2 was carried out, after cooling and exchange of DME for 5.0 mL Et_2O , by enrichment with HCl gas, evaporation, and addition of 3.0 mL DME and 2.5 equiv. oxalyl chloride. The sealed reaction vial was microwave heated to 170 °C for 10 min. ^{*b*} Isolated yield. Purity >95% by LC-ELSD. ^c Reaction was performed on 2.0 mmol scale. ^{*d*} Reaction was performed on 5.0 mmol scale in a 20 mL vial. The temperature and time in step 2 was changed to 145 °C for 25 min.

scaffold as a P3–P2 building block instead of a traditional dipeptide motif. We hoped that the rigidity conferred by the pyrazinone system would compensate, at least to some extent, for the use of an unsubstituted phenylglycine, and result in a new type of inhibitors to be considered as a starting point for further structural optimization.

The 3,5-dichloro-pyrazinone core **4k** was smoothly prepared as described in Table 1. Next, we were interested in the substitution of the C-3 chloro group with a Boc-protected primary amino group (Scheme 4). To accomplish this, we decided to employ a palladiumcatalyzed amide N-arylation reaction using *tert*-butylcarbamate as the nucleophile to afford the Boc-protected aniline derivative **5**. By slightly modifying the conditions reported by Yin and Buchwald³¹ a successful microwave version was developed.³² Thus, the protected N-monoarylated product **5** was obtained in 51% isolated yield after only 30 min of heating at 100 °C using 5 equiv. of *tert*-butylcarbamate as the nucleophile, 5% Pd(OAc)₂ as the Pd source, 8% Xantphos as the ligand, and 2 equiv. caesium carbonate as the base in dry DME (Scheme 4). Full conversion of **4k** was also obtained at higher temperatures but competing cleavage of the Boc group complicated product isolation and diminished the yield. All attempts to further reduce the reaction time to avoid the cleavage of pyrazinone **5** failed, despite investigating different solvents (1,4-dioxane or THF) and an alternative base (K₃PO₄). Ester hydrolysis of **5** followed by standard solution phase peptide coupling, furnished compound **6** as a 50:50 L- and D-Phg epimeric

Entry	Aminonitrile	Product	Isolated yield ^b	Literature yield
1	→ 3e* → NH CN		70%	45% ^c
2	NH 3a CN		64%	_
3	Se CN Se		80%	56% ^c
4	NH CN		86%	56% ^c
5	NH 3j		65%	$60\%^d$
6			56%	38% ^d

Table 2 Microwave-accelerated one-step synthesis of N-1, C-6-disubstituted 3,5-dichloro-2(1H)-pyrazinones (4i,o-s) according
--

^{*a*} The cyclization was carried out with 1.0 mmol **3** in 5.0 mL Et₂O, by enrichment of HCl gas, and thereafter a change of solvent to 3.0 mL DME and addition of 2.5 equiv. oxalyl chloride. The sealed reaction vial was thereafter microwave heated to 170 °C for 10 min. ^{*b*} Isolated yield. Purity >95% by LC/ELSD. ^{*c*} Literature yield: **4i**,²³ **4p**,⁸ **4q**.²⁴ ^{*d*} Literature yield reported for the two-step process.²⁵

mixture in 29% two-step isolated yield (Scheme 4). LiOH-mediated ester hydrolysis of ethyl ester 6 and purification by RP-HPLC gave the final inhibitors 7a and 7b as pure epimers. When evaluated in an *in vitro* assay comprising the full-length NS3 protein,³³ the β -strand mimic containing 7a and 7b were found to be fairly potent inhibitors with K_i -values of 11.0 ± 1.1 µM for 7a and 12.5 ± 2.4 µM for 7b, respectively (Scheme 4). Considering the use of a C-terminal carboxylic acid and an unsubstituted phenylglycine in 7a and 7b, the new P3 pyrazinone-based peptidomimetics are of similar potencies as structurally related, tripeptide inhibitors previously reported by us.³⁰

Conclusion

We have demonstrated that N-1, C-6-functionalized 3,5-dichloro-2(1H)-pyrazinones can be generated in a one-pot, two-step protocol from the corresponding primary amine and aldehyde using a cyanide source, oxalyl chloride, and HCl utilizing





Chart 1 β -Strand peptide (I), and anticipated β -strand formation for a C-5-, C-6-disubstituted 2-(1*H*)-pyrazinone β -strand mimic containing structure (II). HBA—hydrogen bond acceptor, HBD—hydrogen bond donator.



Scheme 4 Synthesis of Hepatitis C Virus NS3 protease inhibitors 7a and 7b.

 2×10 min of high density microwave heating. Compared to the previously reported protocols, this microwave methodology not only increases the reaction speed but actually makes it possible to take advantage of this protocol for modern drug discovery. In the case of sluggish amines, the α -aminonitrile intermediate was purified before microwave-induced cyclization with HCl and oxalyl chloride. A new 3-Boc-amino, N-1-carboxylic acid 2(1*H*)-pyrazinone unit was constructed by palladium(0)-catalyzed microwave-assisted Boc-NH₂ substitution of the chloro group at C-3. Due to the beneficial alignment of the CO- and NH-groups coupled with the rigidity of the pyrazinone ring, the 3-amino-5chloro-2-(1*H*)-pyrazinone N-1-carboxylic acid scaffold was used as a β -strand inducer in two new Hepatitis C Virus NS3 protease inhibitors. The potency of the inhibitors was evaluated in an enzymatic assay ($K_i = 11.0$ and 12.5 μ M, respectively). In view of the speed and robustness of the presented protocols, we anticipate that our work will increase the utilization of the 2(1*H*)-pyrazinone ring system in various medicinal chemistry related applications.

Experimental

General one-pot, two-step procedure for preparation of 2(1H)pyrazinones 4a-n. Method A. A 2.0-5.0 mL Smith microwave vial was charged with amine (1a-h, 1.0 mmol) and was dissolved in 3.0 mL DME. The aldehyde (2a-e, 1.2 mmol) was added and the mixture was stirred for 30 s before adding trimethylsilyl cyanide (1.1 mmol, 138 µL). The vial was sealed and irradiated with microwaves for 10 min at the stated temperatures (step 1, Table 1). The solvent was removed under a stream of nitrogen gas and the residue was dissolved in 5.0 mL diethyl ether. HCl gas was bubbled through the reaction mixture for 5 min followed by evaporation under a stream of nitrogen gas. DME (3.0 mL) and oxalyl chloride $(2.5 \text{ mmol}, 214 \mu\text{L})$ were added and the vial was sealed. After 30 s of stirring, the overpressure was released with a needle before irradiation with microwaves for 10 min at 170 °C (creating a pressure of 10–17 bar). Purification by flash chromatography yielded pure products **4a–n** (>95% by LC-ELSD).

General procedure for preparation of α -aminonitrile 3e*,i-k. Method B. A 2.0–5.0 mL Smith microwave vial was charged with 1 equiv. amine 1e,i-jand 3.0 mL DME. (Diisopropylamine (1.2 equiv.) was added if the amine was a HCl salt). Addition of 1.2 equiv. aldehyde 2a,b, or phenylacetaldehyde (2f) was followed by 30 s stirring before addition of 1.1 equiv. trimethylsilyl cyanide. The vial was sealed and irradiated with microwaves for 10 minutes at the stated temperatures. The solvent was evaporated in vacuum and the crude residue purified by flash chromatography yielding pure products 3e*,i-k (>95% by LC-ELSD).

General procedure for preparation of 2(1*H*)-pyrazinones 4i,os from pure α -aminonitriles. Method C. A 2.0–5.0 mL Smith microwave vial was loaded with 1 mmol α -aminonitrile 3a,e*,ik and 5.0 mL diethyl ether. HCl gas was bubbled through the reaction mixture for 5 min followed by removal of the diethyl ether under a stream of nitrogen gas. DME (3.0 mL) and oxalyl chloride (2.5 mmol, 214 µL) were added and the vial was sealed. After 30 s stirring the overpressure was released and the reaction irradiated by microwaves for 10 min at 170 °C (creating a pressure of 10–17 bar). Purification by flash chromatography yielded pure products 4i,o-s, (>95% by LC-ELSD).

1-Butyl-3,5-dichloro-6-methylpyrazin-2(1*H***)-one (4a). The compound was prepared according to method A, using a 60 °C temperature in step 1. Purification by flash chromatography, eluent ethyl acetate:***iso***-hexane 10:90 to 20:80. Pale yellow oil, 72% yield. ¹H NMR (CDCl₃) δ 4.06 (m, 2H), 2.49 (s, 3H), 1.66 (m, 2H), 1.43 (qm, J= 7.4 Hz, 2H), 0.97 (t, J= 7.4 Hz, 3H); ¹³C NMR (CDCl₃) δ 152.7, 143.5, 135.6, 123.8, 47.4, 29.9, 20.2, 16.6, 13.7. ESI-MS (m/z) 235 (M + H⁺), 471 (2M + H⁺). Anal. Calcd for C₉H₁₂Cl₂N₂O: C, 45.98; H, 5.14; N, 11.91. Found: C, 46.14; H, 5.25; N, 12.04.**

Benzyl 2-(1-cyanoethylamino)acetate (3i)²⁴. The compound was prepared according to method B, using HCl×HGlyOBn (2.0 mmol, 0.402 g), diisopropylamine (2.3 mmol, 400 µL), acetaldehyde **2a** (2.5 mmol, 140 µL), trimethylsilyl cyanide (2.2 mmol, 280 µL) and a temperature of 100 °C. Purification by flash chromatography, eluent ethyl acetate:*iso*-hexane 30:70 to 75:25. Colorless oil, 68% yield. ¹³C-NMR (CD₃OD) δ 172.5, 137.3, 129.7, 129.5 (two peaks), 121.7, 67.8, 49.2, 45.8, 19.6.

Benzyl 2-(3,5-dichloro-6-methyl-2-oxopyrazin-1(2*H*)-yl)acetate (4q)²⁴. The compound was prepared according to method C. Purification by flash chromatography, eluent ethyl acetate:iso-hexane 20:80 to 35:65. Pale yellow solid, 86% yield. ¹³C-NMR (CDCl₃) δ 166.1, 152.7, 143.8, 135.2, 134.6, 129.1, 129.0, 128.7, 124.0, 68.4, 47.6, 16.9. ESI-MS (*m*/*z*) 327 (M + H⁺), 655 (2M + H⁺).

Acknowledgements

We gratefully acknowledge the financial support from the Foundation for Strategic Research, the Swedish Research Council and Knut and Alice Wallenberg's Foundation. We also thank Prof. Helena Danielson and Angelica Ehrenberg for biochemical evaluation of compound 7, Mr Gunnar Wikman for critical review of this paper and Dr. Luke Odell for linguistic advice.

Notes and references

- 1 C. D. Haffner, C. J. Diaz, A. B. Miller, R. A. Reid, K. P. Madauss, A. Hassell, M. H. Hanlon, D. J. T. Porter, J. D. Becherer and L. H. Carter, *Bioorg. Med. Chem. Lett.*, 2008, 18, 4360–4363.
- 2 J. I. Trujillo, H. C. Huang, W. L. Neumann, M. W. Mahoney, S. Long, W. Huang, D. J. Garland, C. Kusturin, Z. Abbas, M. S. South and D. B. Reitz, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 4568–4574.
- 3 C. R. Hopkins, K. Neuenschwander, A. Scotese, S. Jackson, T. Nieduzak, H. Pauls, G. Y. Liang, K. Sides, D. Cramer, J. Cairns, S. Maignan and M. Mathieu, *Bioorg. Med. Chem. Lett.*, 2004, 14, 4819–4823.
- 4 X. J. Zhang, A. C. Schmitt, W. Jiang, Z. Wasserman and C. P. Decicco, Bioorg. Med. Chem. Lett., 2003, 13, 1157–1160.
- 5 J. J. Parlow, B. L. Case, T. A. Dice, R. L. Fenton, M. J. Hayes, D. E. Jones, W. L. Neumann, R. S. Wood, R. M. Lachance, T. J. Girard, N. S. Nicholson, M. Clare, R. A. Stegeman, A. M. Stevens, W. C. Stallings, R. G. Kurumbail and M. S. South, J. Med. Chem., 2003, 46, 4050–4062.
- 6 V. G. Pawar and W. M. De Borggraeve, *Synthesis*, 2006, 2799–2814.
- 7 N. Kaval, P. Appukkuttan, and E. Van der Eycken, in *Microwave-Assisted Synthesis of Heterocycles*, Springer-Verlag, Berlin, 2006, vol. 1, pp. 267–304.
- 8 J. Vekemans, C. Pollerswieers and G. Hoornaert, J. Heterocycl. Chem., 1983, **20**, 919–923.
- 9 W. M. De Borggraeve, B. M. P. Verbist, F. J. R. Rombouts, V. G. Pawar, W. J. Smets, L. Kamoune, J. Alen, E. V. Van der Eycken, F. Compernolle and G. J. Hoornaert, *Tetrahedron*, 2004, **60**, 11597–11612.
- 10 S. V. Pawar, V. G. Pawar, W. Dehaen and W. M. De Borggraeve, Org. Lett., 2008, 10, 4473–4476.

- 11 M. Larhed and A. Hallberg, Drug Discov. Today, 2001, 6, 406-416.
- 12 J. Wannberg, K. Ersmark and M. Larhed, *Top. Curr. Chem.*, 2006, 266, 167–198.
- 13 E. Suna and I. Mutule, Top. Curr. Chem., 2006, 266, 49–101.
- 14 E. V. Van der Eycken and C. O. Kappe, *Microwave-Assisted Synthesis* of *Heterocycles*, Springer-Verlag, Berlin, 2006.
- 15 V. Polshettiwar and R. S. Varma, Acc. Chem. Res., 2008, 41, 629-639.
- 16 J. E. Reiner, D. V. Siev, G. L. Araldi, J. R. J. Cui, J. Z. Ho, K. M. Reddy, L. Mamedova, P. H. Vu, K. S. S. Lee, N. K. Minami, T. S. Gibson, S. M. Anderson, A. E. Bradbury, T. G. Nolan and J. E. Semple, *Bioorg. Med. Chem. Lett.*, 2002, **12**, 1203–1208.
- 17 D. A. Evans and S. A. Biller, Tetrahedron Lett., 1985, 26, 1907–1910.
- 18 S. Dong and P. K. Dasgupta, Atmos. Environ., 1986, 20, 1635–1637.
- 19 A 2.0 mL microwave vial was loaded with 2(1*H*)-pyrazinones 4j-n (0.05–0.15 mmol), (1*S*,2*R*)-*cis*-1-amino-2-indanol (3 equiv.) and acetonitrile (2.0 mL). The reactions were then irradiated by microwaves: 4j at 150 °C for 1.5 h; 4k at 140 °C for 2 h; 4l at 140 °C for 0.5 h; 4m at 160 °C for 2 h; 4n at 160 °C for 1.5 h. The diastereomeric ratios were determined by ¹H-NMR or by HPLC separation with ELSD and ESI-MS detection.
- 20 B. M. P. Verbist, W. M. De Borggraeve, S. Toppet, F. Compernolle and G. J. Hoornaert, *Eur. J. Org. Chem.*, 2005, 2941–2950.
- 21 F. J. R. Rombouts, W. M. De Borggraeve, D. Delaere, M. Froeyen, S. M. Toppet, F. Compernolle and G. J. Hoornaert, *Eur. J. Org. Chem.*, 2003, 1868–1878.
- 22 K. J. Buysens, D. M. Vandenberghe, S. M. Toppet and G. J. Hoornaert, *Tetrahedron*, 1995, **51**, 12463–12478.
- 23 S. M. Vandenberghe, K. J. Buysens, L. Meerpoel, P. K. Loosen, S. M. Toppet and G. J. Hoornaert, J. Org. Chem., 1996, 61, 304–308.
- 24 P. E. J. Sanderson, T. A. Lyle, K. J. Cutrona, D. L. Dyer, B. D. Dorsey, C. M. McDonough, A. M. Naylor-Olsen, I. W. Chen, Z. G. Chen, J. J. Cook, C. M. Cooper, S. J. Gardell, T. R. Hare, J. A. Krueger, S. D. Lewis, J. H. Lin, B. J. Lucas, E. A. Lyle, J. J. Lynch, M. T. Stranieri, K. Vastag, Y. W. Yan, J. A. Shafer and J. P. Vacca, J. Med. Chem., 1998, 41, 4466–4474.
- 25 M. S. South, B. L. Case, R. S. Wood, D. E. Jones, M. J. Hayes, T. J. Girard, R. M. Lachance, N. S. Nicholson, M. Clare, A. M. Stevens, R. A. Stegeman, W. C. Stallings, R. G. Kurumbail and J. J. Parlow, *Bioorg. Med. Chem. Lett.*, 2003, 13, 2319–2325.
- 26 D. Lamarre, P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong and M. Llinas-Brunet, *Nature*, 2003, **426**, 186–189.
- 27 X. J. Zhang, A. C. Schmitt and C. P. Decicco, *Tetrahedron Lett.*, 2002, 43, 9663–9666.
- 28 P. W. Glunz, B. D. Douty and C. P. Decicco, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 785–788.
- 29 I. Schechter and A. Berger, *Biochem. Biophys. Res. Commun.*, 1967, 27, 157–162.
- 30 P. Örtqvist, S. D. Peterson, E. Åkerblom, T. Gossas, Y. A. Sabnis, R. Fransson, G. Lindeberg, U. H. Danielson, A. Karlén and A. Sandström, *Bioorg. Med. Chem.*, 2007, **15**, 1448–1474.
- 31 J. J. Yin and S. L. Buchwald, J. Am. Chem. Soc., 2002, 124, 6043–6048.
- 32 J. Wannberg, D. Dallinger, C. O. Kappe and M. Larhed, J. Comb. Chem., 2005, 7, 574–583.
- 33 A. Poliakov, I. Hubatsch, C. F. Shuman, G. Stenberg and U. H. Danielson, *Protein Expr. Purif.*, 2002, 25, 363–371.